Logo image of ALQGC.PA

QUANTUM GENOMICS SAS-REGR (ALQGC.PA) Stock Price, Forecast & Analysis

Europe - Euronext Paris - EPA:ALQGC - FR0011648971 - Common Stock

0.0721 EUR
0 (-1.77%)
Last: 10/24/2024, 7:00:00 PM

ALQGC.PA Key Statistics, Chart & Performance

Key Statistics
Market Cap5.00M
Revenue(TTM)10.06K
Net Income(TTM)-3.17M
Shares69.34M
Float57.44M
52 Week High0.16
52 Week Low0
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.09
PEN/A
Fwd PE0.02
Earnings (Next)N/A
IPO2009-07-28
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
ALQGC.PA short term performance overview.The bars show the price performance of ALQGC.PA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 50 100 150

ALQGC.PA long term performance overview.The bars show the price performance of ALQGC.PA in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of ALQGC.PA is 0.0721 EUR. In the past month the price increased by 175.19%. In the past year, price decreased by -23.78%.

QUANTUM GENOMICS SAS-REGR / ALQGC Daily stock chart

ALQGC.PA Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to ALQGC.PA. When comparing the yearly performance of all stocks, ALQGC.PA is a bad performer in the overall market: 93.91% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

ALQGC.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to ALQGC.PA. ALQGC.PA may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ALQGC.PA Financial Highlights

Over the last trailing twelve months ALQGC.PA reported a non-GAAP Earnings per Share(EPS) of -0.09. The EPS increased by 87.28% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -84.63%
ROE -726.18%
Debt/Equity 4.49
Chartmill High Growth Momentum
EPS Q2Q%92.58%
Sales Q2Q%N/A
EPS 1Y (TTM)87.28%
Revenue 1Y (TTM)-98.34%

ALQGC.PA Forecast & Estimates

7 analysts have analysed ALQGC.PA and the average price target is 10.2 EUR. This implies a price increase of 14047.02% is expected in the next year compared to the current price of 0.0721.

For the next year, analysts expect an EPS growth of 6121.43% and a revenue growth 1744.53% for ALQGC.PA


Analysts
Analysts34.29
Price Target10.2 (14047.02%)
EPS Next Y6121.43%
Revenue Next Year1744.53%

ALQGC.PA Ownership

Ownership
Inst OwnersN/A
Ins OwnersN/A
Short Float %N/A
Short RatioN/A

About ALQGC.PA

Company Profile

ALQGC logo image Quantum Genomics SA is a biopharmaceutical company, which engages in the development of therapies for cardiovascular diseases. The company is headquartered in Paris, Ile-De-France and currently employs 3 full-time employees. The company went IPO on 2009-07-28. The firm is a biopharmaceutical company dedicated to developing new therapies for unmet medical needs in cardiovascular disease, including high blood pressure and heart failure. Its main activity is in research and development of new therapies for the treatment of hypertension, BAPAI (Brain Aminopeptidase A Inhibitors) oriented in the field of cardiovascular diseases, especially high blood pressure and heart failure. The firm also co-develops products with academic teams, biotechnological research entities, and some of the pharmaceutical and bio-science companies. The firm is involved in four research programs. Quantum Genomics also collaborates with Center for Clinical Investigation 9201 APHP / INSERM of the Georges Pompidou European Hospital in Paris, among others.

Company Info

QUANTUM GENOMICS SAS-REGR

33 rue Marbeuf

Paris ILE-DE-FRANCE FR

Employees: 3

ALQGC Company Website

Phone: 33185347770

QUANTUM GENOMICS SAS-REGR / ALQGC.PA FAQ

What does ALQGC do?

Quantum Genomics SA is a biopharmaceutical company, which engages in the development of therapies for cardiovascular diseases. The company is headquartered in Paris, Ile-De-France and currently employs 3 full-time employees. The company went IPO on 2009-07-28. The firm is a biopharmaceutical company dedicated to developing new therapies for unmet medical needs in cardiovascular disease, including high blood pressure and heart failure. Its main activity is in research and development of new therapies for the treatment of hypertension, BAPAI (Brain Aminopeptidase A Inhibitors) oriented in the field of cardiovascular diseases, especially high blood pressure and heart failure. The firm also co-develops products with academic teams, biotechnological research entities, and some of the pharmaceutical and bio-science companies. The firm is involved in four research programs. Quantum Genomics also collaborates with Center for Clinical Investigation 9201 APHP / INSERM of the Georges Pompidou European Hospital in Paris, among others.


What is the stock price of QUANTUM GENOMICS SAS-REGR today?

The current stock price of ALQGC.PA is 0.0721 EUR. The price decreased by -1.77% in the last trading session.


Does QUANTUM GENOMICS SAS-REGR pay dividends?

ALQGC.PA does not pay a dividend.


How is the ChartMill rating for QUANTUM GENOMICS SAS-REGR?

ALQGC.PA has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 1 out of 10.


Which stock exchange lists ALQGC stock?

ALQGC.PA stock is listed on the Euronext Paris exchange.


Can you provide the PE ratio for ALQGC stock?

QUANTUM GENOMICS SAS-REGR (ALQGC.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.09).


What is the expected growth for ALQGC stock?

The Revenue of QUANTUM GENOMICS SAS-REGR (ALQGC.PA) is expected to grow by 1744.53% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.